Competitive Analysis
and Branding

The numbers are good. Seventy five million American women are in perimenopause, menopause or postmenopause, and roughly six thousand more reach menopause every day. Vasomotor symptoms affect up to eighty per cent of women. Among those with frequent symptoms the median duration is seven point four years, four and a half of them after the final period. Genitourinary symptoms are reported by a quarter to four fifths of postmenopausal women depending on how the question is asked, and unlike hot flushes they are progressive.

The money has been building steadily rather than arriving. One point seven billion dollars went into menopause across the six years from 2020 to 2025. The share of very large American employers offering a menopause benefit went from twenty eight per cent in 2024 to fifty eight per cent in 2026, across employers covering nearly twelve million lives. Ulta lists more than fifty products in its menopause category. The direction is consistent and the rate is increasing, which is a better reason to enter than a spike would be.

The largest single alternative to us is not a product at all. It is the prescription her own physician writes, and that route is growing. The FDA moved to remove the boxed warnings from hormone therapy in November 2025 and approved the first revised labels in February 2026, and prescribing has roughly doubled since 2017. Most of this category has read that as bad news for anything positioned as an alternative. It matters here because it means the consulting room is a live competitor, not a legacy one.

And the field is emptier than it looks from inside it. Mayo Clinic surveyed nearly five thousand American women aged forty five to sixty and found eighty seven per cent had not sought medical care for their symptoms, with only about one in four receiving any treatment. The category is loud to us because we stare at it all day. To her it is close to silent.

On any given afternoon she can weigh a prescription, a supplement, a moisturiser and a vaginal insert against each other, at anything from seven dollars a month to six hundred and fifty. Format is not her obstacle and an unfamiliar ingredient is not her obstacle. Both are already normal to her in this aisle.

She does not shop in a cannabinoid aisle. The brands that shape what she expects a women's health product to cost, to promise and to look like are mostly not cannabinoid brands at all.

Bonafide is the commercial proof that the unglamorous end of this category is where the money is. It sold to Pharmavite for four hundred and twenty five million dollars as the least charming brand in the field, leads with a hormone free badge, and explains neurokinin receptors to its customers without anyone deciding it is in the receptor business. Midi Health was valued at a billion dollars on prescriber authority rather than brand charm.

Alloy, Evernow and Stripes carry near identical wording on the care you deserve. Womaness uses we see you, we hear you as a brandline. Elektra Health uses smashing the taboo as its. Kindra runs a badge stack, Joylux uses confidence restored, and Phenology's entire visual identity was built by Pentagram from the idea that menopause is another chapter in your life, illustrated with butterflies for transformation.

Telehealth is where the price anchor comes from. Alloy, Wisp, Midi, Interlude and Hers deliver a prescription to the door for twenty to forty dollars a month without insurance. That is the number most women in this market now carry in their heads, and it was not set by anyone selling a suppository.

List prices, not promotional, taken from each brand's own product pages. The pack price is the number a brand advertises. The number that decides value is what she receives for it and how much of a month it covers.

Disclosure is the one axis in this category that can be compared without argument. Either a brand names a cannabinoid and puts a milligram figure against it, or it does not. This is what every brand publishes on its own product pages.

The problem is old enough to have been documented for a decade. NPR reported on it in 2015, quoting Dr Wulf Utian on the organisations and, in his words, snake oil salesmen climbing on the bandwagon, and Dr Janet Pregler on the reflex to sell this to as many people as possible. The same piece records the reaction that should worry any brand built on symptom maximising, from a woman who said she thought there was something wrong with her because she was not having terrible symptoms.

The look is not accidental either. Fast Company has codified the menopause house style: vibrant colour, organic shapes, hand drawn illustration, a friendly serif and a refined wordmark, naming Alloy, Evernow, Stripes, Phenology and Womaness. Pentagram's account of designing Phenology describes starting from the idea that menopause is another chapter in your life, and the illustration system uses butterflies for transformation.

The messaging has been classified. Academic analysis of twenty menopause advertisements published between 2019 and 2024 found three repeating instructions: defy it, disavow it, embrace it. All three put the burden on the individual woman and restate the same idea about how she is supposed to look.

The commercial version has a name in the trade press. Menowashing. Put the word meno in front of a product and the price can double, which is how menopause shampoo and menopause chocolate came to exist. The part that matters is the second half of it. People can see through it.

What she wants has been measured, and the American data is clear. AARP finds that sixty six per cent of people over fifty prefer brands featuring mixed ages, seventy three per cent prefer brands catering to all ages rather than only to older people, and seventy two per cent of women prefer age diverse advertising. Being spoken to as a separate category is itself part of what she objects to.

Hone Health asked a thousand American adults aged thirty five to sixty five which words they would abolish. Old came first by a distance. Midlife made the top ten. The number underneath matters more: only a fifth of the objection is about appearance, and over sixty per cent is about identity, energy and mattering. Seventy three per cent feel positive about this stage of life and seventy one per cent think their best years are now or ahead.

Menopause. The evidence points two ways and both are right, because they measure different surfaces. Shoppers say they want to be able to find products labelled for menopause, and that brands do not signpost them well enough. Interviews with menopausal women aged forty nine to sixty one found the opposite reaction to being targeted explicitly: isolation, discomfort, and fear that public association with menopause exposes a stigmatised identity, with some women rejecting brands to keep their anonymity. It is a search word and a shelf word. It is not a bathroom cabinet word.

Hormone free. The entry ticket, not a differentiator. It is Bonafide's lead badge, Hello Again's headline, Kindra's badge stack and Joylux's descriptor. Four competitors have already built on it.

Wellness. Devalued but not toxic. Usable as a category descriptor and unusable as a promise. The whole menowashing criticism is, at bottom, a wellness credibility crisis.

Cannabinoid, hemp and CBD. Three live strategies, and they produce three different companies. Foria keeps cannabis as heritage at the brand layer and explicit at the product layer. Hello Again leads with CBD in the page title because it sells through dispensaries, where the association qualifies rather than disqualifies. Vella has removed CBD and hemp from its homepage entirely and replaced the credential with the fact that its team developed Viagra and Cialis.

Old, midlife, and every word for decline. Hone Health put old first among words people want abolished and midlife in the top ten, and found the objection is about mattering rather than looks.

We are also the only brand in the field that publishes ten cannabinoids by name, and the only one that will ship a certificate matched to her lot number. We publish the profile and the total. We do not publish the split, because the split is the formulation.

The argument is simple enough for a customer. The endocrine system produces the hormones. It does not work in isolation, and one of the systems alongside it is the endocannabinoid system, whose job is to hold things steady. Mood, sleep, temperature, stress, and in women the monthly and life stage rhythms. It works through receptors found almost everywhere in the body and the body makes its own compounds to switch them on and off.

The reason she has never heard of it is a matter of record. It was identified in the early 1990s, after most practising doctors finished training. It is one of the most widespread receptor networks in the human body and it is missing from the education of the people she asks for advice. That is not a marketing angle. It is a genuine gap in what she has been told, and filling it is the most useful thing we can do for her before she has bought anything.

There is precedent in her own aisle. Bonafide explains neurokinin receptors to its customers and sold for four hundred and twenty five million dollars. Nobody decided Bonafide was in the receptor business. Teaching the mechanism did not narrow the brand. It gave the product a reason to exist that a competitor could not copy by changing a label.

These are not alternatives. Direction 2 is the evidence that makes Direction 1 believable, and Direction 1 is what makes Direction 3 sound like a decision rather than an oddity. The order matters more than the choice. Teach the system, prove the box, then explain the route.

These are the decisions the competitor picture makes urgent. They are not the whole decision list.